Given the effects of CHIR99021 treatment in T98G cells in terms of cell viability and metabolic state, we further investigated whether this pharmacological modulation of the circadian clock could serve to improve the standard temozolomide (TMZ) treatment for GBM patients. This evidence concerns the gene CLOCK and glioblastoma.